Bernstein analyst Florent Cespedes maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK620.00.
The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Malgré les reculs politiques, de nombreuses grandes entreprises européennes publient déjà leurs reportings CSRD.
Two counties in the Charlotte area have filed lawsuits in the last few weeks over the price of insulin. Gaston County and ...
A new study led by researchers from Boston University Chobanian & Avedisian School of Medicine has found there is no consensus in how clinical experts interpret CGM reports from people without ...
While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...